National Comprehensive Cancer Network

About NCCN

NCCN Holds its First Annual International Day

The National Comprehensive Cancer Network® (NCCN®) recently held its first Annual International Day in conjunction with the NCCN 18th Annual Conference:  Advancing the Standard of Cancer Care™. Last month, more than 20 physicians from across Latin America and three physicians from Turkey came to Hollywood, Florida to meet with NCCN Guidelines Panel members and NCCN staff to discuss the consideration of regional adaptations necessary for effective utilization of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in their respective countries. The discussions specifically focused on application of the NCCN Guidelines® for Colorectal Cancer in oncology care in Latin American and potential modifications to NCCN Guidelines for Melanoma for use in Turkey. The NCCN International Day was held on March 17, 2013; however, many of the physicians arrived earlier in the week and attended the NCCN Annual Conference clinical sessions, as well.

"We at NCCN value very highly our collaborative efforts with our international colleagues to improve the quality of care of patients with cancer," said Robert W. Carlson, MD, CEO, NCCN. "We are gratified that the NCCN Guidelines are highly relevant on a global basis, and we look forward to further expanding our international programs."

Participating in the discussion regarding NCCN Guideline application and utilization in Latin America include:

Al B. Benson, III, MD
Chair of the NCCN Colon Cancer Guidelines Panel
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Alan P. Venook, MD
Member of the NCCN Colon Cancer Guidelines Panel
UCSF Helen Diller Family Comprehensive Cancer Center

Carlos Vargas, MD
Fundación Santafé de Bogotá
Bogotá, Colombia

Jesús Insuasty, MD
Hospital Universitario de Santander
Bucaramanga, Colombia

Andres Gonzalez, MD
Instituto Nacional de Cancerología
Bogotá, Colombia

Jorge Sabbaga, MD
ICESP e HSL
Sao Paulo, Brasil

Stephen Doral Stefani, MD
Unimed
Porto Alegre, Brasil

Rene Gansl, MD
Hospital Israelita Albert Einstein
Sao Paulo, Brasil

Alejandro Juárez, MD
ISSSTE 20 de Noviembre
Mexico City, Mexico

Alejandro Silva, MD
IMSS Oncología Siglo XXI
Mexico City, Mexico

Paola Montenegro, MD
Instituto Nacional de Enfermedades Neoplásicas
Lima, Peru

Karen Kubicek Falope, MD
Hospital Militar Venezuela
Caracas, Venezuela

Patricia Miren De Arbeloa, MD
Centro Clínico San Cristobal Edo. Táchira
San Cristóbal, Venezuela

Eva Lezcano, MD
Instituto de Prevención Social (IPS)
Asunción, Paraguay

Germán Calderillo, MD
INCAN
Mexico City, Mexico

Miguel Quintana, MD
Hospital Naval
Mexico City, Mexico

Mario Pérez, MD
PEMEX
Mexico City, Mexico

Paula Cabrera, MD
ISSEMYM
Toluca, Mexico

Guillermo Mendez, MD
Hospital de Gastroenterología
Buenos Aires, Argentina

Mariano Dioca, MD
Instituto Oncológico Ángel Roffo
Buenos Aires, Argentina

Francisco Manuel Perrotta, MD
Instituto de Prevención Social (IPS)
Asunción, Paraguay

 

Participating in the discussion regarding NCCN Guideline application and utilization in Turkey include:

Daniel G. Coit, MD
Chair of the NCCN Melanoma Guidelines Panel
Memorial Sloan-Kettering Cancer Center

Anthony J. Olszanski, MD
Member of the NCCN Melanoma Guidelines Panel
Fox Chase Cancer Center

Berk Ozdemir, MD
Ankara, Turkey

Alper Sevinc, MD
Gaziantep Oncology Hospital

Deniz Yuce, MD
Hacettepe University, Cancer Institute, Department of Preventive Oncology

 

Nearly half of all registered users of the NCCN Guidelines on NCCN.org report that they live outside the United States.  NCCN regularly works with thought leaders throughout the world to review the NCCN Guidelines with consideration of metabolic differences in populations, local accessibility, and regulatory status of health care technologies used in cancer care in the specified country. The resulting foreign editions, regional adaptations, and consensus statements of the NCCN Guidelines are considered NCCN Guidelines derivatives.  The modified NCCN Guidelines are then translated into the local language with specified modifications, published on NCCN.org, and distributed locally to aid clinicians in determining appropriate and effective cancer care.

In addition to regional modifications, last year the NCCN Guidelines were translated into seven foreign languages, and permission was given for distribution in more than 20 countries around the world. The entire library of resources, including all translations and adaptations are available free-of-charge for clinical use on NCCN.org (http://www.nccn.org/international/international_adaptations.aspx), or via the Virtual Library of NCCN Guidelines formatted for iPad and Android Tablet Computers (http://www.nccn.org/apps/default.aspx).

If you have any questions regarding the NCCN International program or related activities, please contact Jon Larsen, MPP, Manager, Global Business Development at Larsen@nccn.org.

Permission for use and/or distribution the NCCN Guidelines globally can be requested here: http://www.nccn.org/about/permissions/